Fred D. Lublin

A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (March 2015) (Learn how and when to remove this message)

Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.^[1]

Lublin is Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York and Saunders Family Professor of Neurology at Mount Sinai School of Medicine. He sits on the board of directors at both the National Multiple Sclerosis Society and MS Hope for a Cure and has been listed in "Who's Who in Frontiers of Science and Technology" and New York Magazine's "Best Doctors" issue every year since 2000.^[2][3][4]

According to his employer, in 2004, Lublin secured one of the largest grants ever given for MS research, a $25 million grant from the NIH, to study the benefits of combination drug therapy.^[5] He is a consultant to the National Institutes of Health and to pharmaceutical/biotech companies in all phases of drug development in preparation for presentation to the FDA and their advisory panels.

He is the author of numerous scientific publications including Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey, one of the most frequently cited works in the field of multiple sclerosis.^[6]

Lublin was born in 1946 in Philadelphia, Pa. He graduated from Temple University in 1968 and Jefferson Medical College in 1972. He completed his internship in internal medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center and his residency at the New York Hospital, Cornell Medical Center.

He joined the staff at Mount Sinai Medical Center in April 2000.

Lublin was among the first in the United States to study Interferon β-1b and its ability to treat the relapsing-remitting form of multiple sclerosis; in 1993, IFN β-1b was approved by the U.S. Food and Drug Administration for that very purpose.^[7]

He is the author of nineteen chapters, 136 publications and one text, and is a member of dozens of medical societies including: the National Multiple Sclerosis Society; the MSSM General Clinical Research Center Advisory Committee; and the executive committee of the International Medical & Scientific Board of the Multiple Sclerosis International Federation.

Partial list:

• Combination Therapy in Multiple Sclerosis, 2003–2012, National Institutes of Health^[8]
• Double-Blind, Placebo-Controlled, 20-Week Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis, 2002–Present, Acorda Therapeutics^[9]
• Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography Treatment on Relapses in Patients with Multiple Sclerosis, 2002–Present, Bayer^[10]
• Study to Evaluate IV and Oral Steroids for MS Attacks, 2002–2005, National Multiple Sclerosis Society^[8]
• Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-1 88667 Administered to Subjects with Relapsing-Remitting Multiple Sclerosis, 2001–2003, Bristol-Myers Squibb

Partial list:

• Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS (January 1996). "Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference". Neurology. 46: 12–8. doi:10.1212/wnl.46.1.12. PMID 8559358. S2CID 24692780.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Lublin FD, Reingold SC (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46: 907–11. doi:10.1212/wnl.46.4.907. PMID 8780061. S2CID 40213123.
• Lublin FD, Reingold SC (March 1997). "Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 48: 572–4. doi:10.1212/wnl.48.3.572. PMID 9065528. S2CID 46647702.
• Croul S, Lublin FD, Del Valle L; et al. (July 2000). "The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model". J. Neuroimmunol. 106 (1–2): 181–8. doi:10.1016/s0165-5728(00)00193-4. PMID 10814796. S2CID 46109869.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Kalman B, Lublin FD (May 2001). "Spectrum and classification of inflammatory demyelinating diseases of the central nervous system". Curr Neurol Neurosci Rep. 1 (3): 249–56. doi:10.1007/s11910-001-0027-5. PMID 11898526. S2CID 25496391.
• Lublin FD, Reingold SC (May 2001). "Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS". Ann. Neurol. 49: 677–81. doi:10.1002/ana.1025. PMID 11357961. S2CID 26680369.
• Tullman MJ, Lublin FD, Miller AE (2002). "Immunotherapy of multiple sclerosis--current practice and future directions". J Rehabil Res Dev. 39: 273–85. PMID 12051470.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Lublin FD (June 2002). "The diagnosis of multiple sclerosis". Curr. Opin. Neurol. 15 (3): 253–6. doi:10.1097/00019052-200206000-00005. PMID 12045721. S2CID 29384845.
• Lublin F.D. (2002). "Modernize Your Approach to Multiple Sclerosis". Practical Neurology. 1: 44–49.
• Lublin FD, Baier M, Cutter G (December 2003). "Effect of relapses on development of residual deficit in multiple sclerosis". Neurology. 61 (11): 1528–32. doi:10.1212/01.wnl.0000096175.39831.21. PMID 14663037. S2CID 9958613.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Lublin F (September 2005). "History of modern multiple sclerosis therapy". J. Neurol. 252 Suppl 3: iii3 – iii9. doi:10.1007/s00415-005-2010-6. PMID 16170498. S2CID 16933337.
• Lublin F (November 2005). "Multiple sclerosis trial designs for the 21st century: building on recent lessons". J. Neurol. 252 Suppl 5: v46–53. doi:10.1007/s00415-005-5008-1. PMID 16254702. S2CID 189867505.
• Lublin FD (May 2007). "The incomplete nature of multiple sclerosis relapse resolution". J. Neurol. Sci. 256 Suppl 1: S14–8. doi:10.1016/j.jns.2007.01.062. PMID 17337274. S2CID 42062273.
• DeAngelis T, Lublin F (2008). "Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies". Mt. Sinai J. Med. 75 (2): 157–67. doi:10.1002/msj.20030. PMID 18500719.
• Fazekas F, Lublin FD, Li D; et al. (July 2008). "Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial". Neurology. 71 (4): 265–71. doi:10.1212/01.wnl.0000318281.98220.6f. PMID 18645164. S2CID 28882940.{{cite journal}}: CS1 maint: multiple names: authors list (link)

• Mount Sinai Medical Center – About the Corinne Goldsmith Dickinson Center for Multiple Sclerosis
• Mount Sinai School of Medicine
• National Multiple Sclerosis Society (U.S.)
• International Federation of Multiple Sclerosis Societies
• The Multiple Sclerosis Cooperative Research Group
• American Neurological Association
• American Academy of Neurology
• World Federation of Neurology
• International Brain Research Organization
• International Society of Neuroimmunology
• European Charcot Foundation
• Transcript: Fred D. Lublin interview on "Larry King Live"